jueves, 22 de marzo de 2018

Top 10 Pharmaceutical companies 2018 (III) IgeaHub





Ver anterior:
Top 10 Pharmaceutical companies 2018 (II)






 

Merck & Co. (U.S.)

Merck, research and development company, known as MSD outside the United States and Canada, offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. Merck offers medicines in oncology, fertility, neurodegenerative diseases, and endocrinology. 
In 2017, top 3 best-selling drugs include Januvia / Janumet, Keytruda, and Gardasil / Gardasil 9.

Novartis (Switzerland)

Novartis is a global healthcare company based in Basel, Switzerland. The company’s portfolio includes innovative biological therapies and pharmaceuticals in several disease areas including oncology, cardiology, neurology, immunology, eye care, generic and bio-similar medicines. 
In 2017, top 3 best-selling drugs include Gilenya, Cosentyx, and Glivec.

Gilead Sciences (U.S.)

Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. Gilead Sciences focused on virology, hepatology, hematology, oncology, cardiovascular, inflammation and respiratory diseases. 
In 2017, top 3 best-selling drugs include Harvoni, Epclusa, and Truvada.

GlaxoSmithKline (U.K.)

GlaxoSmithKline is research-focused pharmaceutical company engaged in discovering, manufacturing and distributing pharmaceutical products including prescription medicines, vaccines and consumer healthcare. It offers medicines in cardiovascular disease, gynecology, diabetes, anti-infective, dermatology, and respiratory diseases. 
In 2017, top 3 best-selling drugs include Seretide/Advair, Triumeq, and Tivicay.

Amgen (U.S.)

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California that discovers and develops innovative therapies in both biopharmaceuticals and small molecule drugs. 
In 2017, top 3 best-selling drugs include Enbrel, Neulasta, and Aranesp.

Sources: SEC filings, companies websites, and annual reports.

No hay comentarios: